A New Therapeutic Era in the Management of Diabetic Kidney Disease

      Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) worldwide. After 2 decades of negative trials, in the last few years there has been a major and welcome shift in the therapeutic options to treat DKD. Nephrologists will be in the forefront of implementation of these new therapies as well as in the education of their colleagues and patients on the benefits and possible side effects of these novel therapies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal


      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Eberly L.A.
        • Yang L.
        • Eneanya N.D.
        • et al.
        Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US.
        JAMA Netw Open. 2021; 4: e216139
        • Morton J.I.
        • Ilomki J.
        • Magliano D.J.
        • Shaw J.E.
        The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.
        Diabetologia. 2021; 64: 349-360
        • Whyte M.B.
        • Hinton W.
        • McGovern A.
        • et al.
        Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: a retrospective cohort analysis.
        PLoS Med. 2019; 16: e1002942